Icon

LYRICA CR - (82.5,165 mg; Tablet, Extended Release)

Pregabalin Pfizer
82.5,165 mg; Tablet, Extended Release
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
None
More Than 5
More Than 5
Used to treat pain caused by nerve damage due to diabetes or shingles (herpes zoster) infection
Yes
*** ****** ***** * *********** ******** ******* * *********** **** *** *** **** ******** **** *** ******** ’***, ’*** ** ’*** *******
LYRICA CR Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
*** ****** *** ********* **** *** *** ********* *** ********* **** ***
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*** ****** *** \ ********* *** ********* *** ********* ******** ******** ** *** **, ****
  1. *** *, **** : *** ****** ******** ****** ***** **'* **** ** ****** **** ******* ******* (*** *,****) *** ******* (*** *,****)
  2. *** **, **** : *** ****** ******** ****** ***** **'* **** ** ****** **** ****** ******** (*** *,****)
  3. *** *, **** : *** ****** ***** * *********** ******** ******* * *********** **** *** *** **** ******** **** *** ******** ’***, ’*** ** ’*** *******

LYRICA CR - (330mg; Tablet ER)

Pregabalin Pfizer
330mg; Tablet ER
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
More Than 5
More Than 5
Used to treat pain caused by nerve damage due to diabetes or shingles (herpes zoster) infection
Yes
*** ****** ***** * *********** ******** ******* * *********** **** *** *** **** ******** **** *** ******** ’***, ’*** ** ’*** *******
LYRICA CR Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
*** ****** *** ********* **** *** *** ********* *** ********* **** ***
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*** ****** *** \ ********* *** ********* *** ********* ******** ******** ** *** **, ****
  1. *** **, **** : *** ****** ******** ****** ***** **'* **** ** ****** **** ******* ******* (*** *,****) *** ******* (*** *,****)
  2. *** **, **** : *** ****** ******** ****** ***** **'* **** ** ****** **** ****** ******** (*** *,****)
  3. *** *, **** : *** ****** ***** * *********** ******** ******* * *********** **** *** *** **** ******** **** *** ******** ’***, ’*** ** ’*** *******

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.